IRVINE, Calif., Oct. 26, 2017 /PRNewswire/ — Cryoport, Inc. (NASDAQ: CYRX, CYRXW) (“Cryoport” or the “Company”), the world’s leading cold chain logistics company serving the life sciences industry, today announced the launch of a new website supporting its CryoStork(SM) cryogenic logistics solutions offering for the Reproductive Health Market, located at www.myCryoStork.com. Cryoport’s CryoStorkSM solutions are revolutionary as they are the fastest, most reliable solutions on the market for Reproductive Health patients, providing express transportation worldwide for commodities such as embryos, eggs, sperm and reproductive tissues.
Cryoport’s suite of logistics solutions have supported the Reproductive Health market since 2010 and, in March, 2017, the Company expanded its solutions to include its qualified and secure CryoStorkSM cryogenic logistics solutions to meet the growing demand for efficient and dependable logistics services in the Reproductive Health Market. These solutions are used by patients undergoing in vitro fertilization treatments, other forms of assisted reproductive technology or simply needing to move their valuable reproductive assets. The new CryoStorkSM website provides information for patients and fertility clinics to better understand how Cryoport’s powerful and efficient end-to-end cold chain logistics solutions, powered by world class cryogenic logistics, composed of advanced packaging and information technology, and a cutting-edge logistics management platform, can meet the logistics needs of their clients and patients.
“The medical field has made tremendous technological advances in combating infertility and managing fertility, which, combined with increasing fertility cases and dramatic changes in societal attitudes toward these issues, has led to rapid growth in the Reproductive Health Market, worldwide,” commented Mr. Jerrell Shelton, Chief Executive Officer of Cryoport, Inc. “We have expanded our suite of cold chain logistics solutions to include CryoStorkSM in order to meet the largely unmet need for premium quality cold chain logistics solutions to support the assisted reproductive technology market, which, according to Transparency Market Research, was valued at $2.2 billion in 2016 and is estimated to reach $3.8 billion by 2024. Our cutting edge CryoStorkSM solutions keeps reproductive commodities at cryogenic conditions, thereby, eliminating temperature excursions and reducing the risk of embryo, sperm, or egg degradation.
“For patients using our logistics solutions to manage their most precious life source commodities, such as embryos, reliability and quality is paramount. Our Reproductive Health solutions use the same proven technology employed by our biopharmaceutical clients, including the Cryoport Express® Dry Shippers and our proprietary SmartPak II™ Condition Monitoring system and the Cryoportal™ Management Platform, which offers real time, documented Chain-of-Condition and Chain-of-Custody tracking along with monitoring data. This is the fastest and most reliable solution on the market and we are excited about the opportunity to support the market and to grow this part of our business,” concluded Mr. Shelton.
About Cryoport, Inc.
Cryoport is the life sciences industry’s most trusted global provider of cold chain logistics solutions for temperature-sensitive life sciences commodities, serving the biopharmaceutical market with leading-edge logistics solutions for biologic materials, such as regenerative medicine, including immunotherapies, stem cells and CAR-T cells. Cryoport’s solutions are used by points-of-care, CRO’s, central laboratories, pharmaceutical companies, manufacturers, university researchers et al; as well as the reproductive medicine market, primarily in IVF and surrogacy; and the animal health market, primarily in the areas of vaccines and reproduction. Cryoport’s proprietary Cryoport Express® Shippers, Cryoportal™ Logistics Management Platform, leading-edge SmartPak II™ Condition Monitoring System and geo-sensing technology, paired with unparalleled cold chain logistics expertise and 24/7 client support, make Cryoport the end-to-end cold chain logistics partner that the industry trusts.
Cryoport is dedicated to
- simplifying global cold chain logistics through innovative technology, unmatched monitoring and data capture and support, including consulting;
- delivering the most advanced temperature controlled logistics solutions for the life sciences industry; and
- providing vital information that provides peace of mind throughout the life of each logistics process.
For more information about Cryoport, Inc. visit www.cryoport.com or sign up to follow @cryoport on Twitter at www.twitter.com/cryoport. For more information about CryoStork(SM)Next Flight Out, visit www.MyCryoStork.com.
Forward Looking Statements
Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.’s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company’s actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the Company’s cash flow, market acceptance risks, and technical development risks. The Company’s business could be affected by a number of other factors, including the risk factors listed from time to time in the Company’s SEC reports including, but not limited to, the Transition Report on Form 10-K for the nine months ended December 31, 2016 filed with the SEC. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.